The drugmaker received a request for information from the FTC as part of a preliminary investigation, Mylan told Bloomberg Monday.
The FTC will investigate whether Mylan improperly extended EpiPen patents by making small, unnecessary changes to the device to block generic competition, a source told Bloomberg. The agency will also assess whether Mylan entered any agreements that delayed cheaper versions of the EpiPen from entering the market, the unnamed source said.
A Mylan spokesperson said the company has not acted improperly to prevent generic competition, according to the report.
The investigation is still in its early stages and may not result in an enforcement action, the unnamed source told Bloomberg.
More articles on supply:
Viewpoint: Why a Silicon Valley mindset is wrong for the FDA
Amazon seeks legal options to counter immigration ban: 4 things to know
Senate Dems: Hiring freeze could stall 21st Century Cures Act
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.